There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.
作者信息
Lowenstein P R, Yadav Viveka Nand, Chockley Peter, Castro Maria
机构信息
Department of Neurosurgery and Department of Cell and Developmental Biology, Cancer Center, Program in Cancer Biology, Immunology, and Neuroscience, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Neurosurgery and Department of Cell and Developmental Biology, Cancer Center, Program in Cancer Biology, Immunology, and Neuroscience, University of Michigan Medical School, Ann Arbor, Michigan, USA.
出版信息
Mol Ther. 2014 Feb;22(2):246-247. doi: 10.1038/mt.2013.297.
Abstract
摘要
相似文献
1
There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.
Mol Ther. 2014 Feb;22(2):246-247. doi: 10.1038/mt.2013.297.
2
AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.
Mol Ther. 2014 Feb;22(2):329-337. doi: 10.1038/mt.2013.266. Epub 2013 Nov 21.
3
Regulation of MHC class II expression in the central nervous system.
Microbes Infect. 1999 Sep;1(11):893-902. doi: 10.1016/s1286-4579(99)00228-2.
4
Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells.
Neurol Res. 2005 Dec;27(8):820-6. doi: 10.1179/016164105X49454.
5
Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system.
Neuropharmacology. 2004 Apr;46(5):734-42. doi: 10.1016/j.neuropharm.2003.11.007.
6
Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver.
Gene Ther. 2011 Apr;18(4):403-10. doi: 10.1038/gt.2010.157. Epub 2010 Dec 9.
7
AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells.
Mol Ther. 2014 Jan;22(1):28-41. doi: 10.1038/mt.2013.134. Epub 2013 Jun 19.
8
Recombinant adeno-associated viral vectors in the nervous system.
Hum Gene Ther. 2005 Jul;16(7):781-91. doi: 10.1089/hum.2005.16.781.
9
Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction.
Hum Gene Ther. 2015 Jan;26(1):1-13. doi: 10.1089/hum.2014.070.
10
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.
Gene Ther. 2003 Jun;10(11):955-63. doi: 10.1038/sj.gt.3302037.
引用本文的文献
1
Impact of age and vector construct on striatal and nigral transgene expression.
Mol Ther Methods Clin Dev. 2016 Dec 7;3:16082. doi: 10.1038/mtm.2016.82. eCollection 2016.
2
Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.
J Neurophysiol. 2016 Apr;115(4):2124-46. doi: 10.1152/jn.01131.2015. Epub 2016 Feb 17.
本文引用的文献
1
AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.
Mol Ther. 2014 Feb;22(2):329-337. doi: 10.1038/mt.2013.266. Epub 2013 Nov 21.
2
Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
Blood. 2013 Jul 4;122(1):23-36. doi: 10.1182/blood-2013-01-306647. Epub 2013 Apr 17.
3
Trophic factor gene therapy for Parkinson's disease.
Mov Disord. 2013 Jan;28(1):96-109. doi: 10.1002/mds.25344.
4
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.
Mol Ther. 2013 Jan;21(1):158-66. doi: 10.1038/mt.2012.167. Epub 2012 Aug 28.
5
Parkinson's disease: gene therapies.
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a009431. doi: 10.1101/cshperspect.a009431.
6
Gene therapy for Parkinson's disease: from non-human primates to humans.
Curr Opin Mol Ther. 2010 Oct;12(5):519-29.
7
Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.
Mol Ther. 2008 Feb;16(2):343-51. doi: 10.1038/sj.mt.6300375. Epub 2008 Jan 8.
8
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.
Curr Gene Ther. 2007 Oct;7(5):347-60. doi: 10.2174/156652307782151498.
9
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.
Mol Ther. 2007 Dec;15(12):2154-63. doi: 10.1038/sj.mt.6300305. Epub 2007 Sep 25.
10
Autoimmune anemia in macaques following erythropoietin gene therapy.
Blood. 2004 May 1;103(9):3303-4. doi: 10.1182/blood-2003-11-3845. Epub 2004 Jan 22.
Zotero 插件